Fluoroquinolones in the treatment of meningitis

Current Infectious Disease Reports

Volumn 5, Issue 4, 2003, Pages 329-336

  Cottagnoud, Philippe ^a   Täuber, Martin G ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFTRIAXONE; CIPROFLOXACIN; CLINAFLOXACIN; DK 507K; GARENOXACIN; GATIFLOXACIN; GEMIFLOXACIN; GENTAMICIN; GREPAFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MEROPENEM; MOXIFLOXACIN; NALIDIXIC ACID; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RUFLOXACIN; SPARFLOXACIN; TOSUFLOXACIN; TROVAFLOXACIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; WCK 771A;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL MENINGITIS; BACTERICIDAL ACTIVITY; CEREBROSPINAL FLUID; CLINICAL TRIAL; CONCENTRATION RESPONSE; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENTIATION; DRUG STRUCTURE; EXPERIMENTAL INFECTION; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HUMAN; IN VITRO STUDY; NEISSERIA MENINGITIDIS; NONHUMAN; PENICILLIN RESISTANCE; PHARMACODYNAMICS; REVIEW; STREPTOCOCCUS INFECTION;

EID: 1842862666     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-003-0011-0     Document Type: Review

References (76)

1. Tunkel AR, Scheld WM: Treatment of bacterial meningitis. Curr Infect Dis Rep 2002, 4:6-16.
2. de Gans J, van de Beek D: Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002, 347:1549-1556.
3. Cabellos C, Martinez-Lacasa J, Martos A, et al.: Influence of dexamethasone on efficacy of ceftriaxone and vancomycin therapy in experimental pneumococcal meningitis. Antimicrob Agents Chemother 1995, 39:2158-2160.
4. Novak R, Henriques B, Charpentier E, et al.: Emergence of vancomycin tolerance in Streptococcus pneumoniae. Nature 1999, 399:590-593.
5. McCullers JA, English BK, Novak R: Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae from cerebrospinal fluid of a patient who developed recrudescent meningitis. J Infect Dis 2000, 181:369-373.
6. Neu HC: Major advances in antibacterial quinolone therapy. Adv Pharmacol 1994, 29:227-262.
7. Gootz TD, Brighty KE: Fluoroquinolone antibacterials: SAR, mechanism of action, resistance and clinical aspects. Med Res Rev 1996, 16:433-436.
8. Domagala JM, Hanna LD, Heifetz CL, et al.: New structure-activity relationships of the quinolone antibacterials using the target enzyme: the development and application of a DNA gyrase assay. J Med Chem 1986, 29:394-404.
9. Wolfson JS, Hooper DC: The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother 1985, 28:581-586.
10. Culberston TP, Domagala JM, Hagen SE, et al.: Structure-activity relationship of the quinolone antibacterials: the nature of the C7-side chain. In International Telesymposium on Quinolones. Edited by Fernandes PB, Barcelona: JR Prous Science Publishers; 1989:47-71.
11. Kato J, Nishimura Y, Niki H, et al.: New topoisomerase essential for chromosome segregation in E. coli. Cell 1990, 63:393-404.
12. Menzel R, Gelbert M: Regulation of genes for E. coli DNA gyrase: homeostatic control of DNA supercoiling. Cell 1987, 34:105-113.
13. Gellert M, Mizuuchi D, O'Dea MH, et al.: Nalidixic acid resistance. A second genetic character involved in DNA gyrase activity. Proc Natl Acad Sci U S A 1977, 74:4772-4776.
14. Sugino A, Peebles CL, Kruezer KN, Cozzarelli NR: Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme. Proc Natl Acad Sci U S A 1977, 74:4767-4771.
15. Huang WM: Bacterial diversity based on type II DNA topoisomerase genes. Ann Rev Genet 1996, 30:79-107.
16. Peng H, Marians K: E. coli topoisomerase IV: purification, characterization, subunit structure and subunit interactions. J Biol Chem 1991, 268:24481-24490.
17. Marians KJ: Replications fork progression. In E. coli and Salmonella Cellular and Molecular Biology. Edited by Neidhart FC, Washington DC: American Society of Microbiology, 1996:749-763.
18. Shen L, Pernet AG: Mechanism of inhibition of DNA gyrase by analogs of nalidixic acid: the target of the drugs is DNA. Proc Natl Acd Sci U S A 1985, 82:307-311.
19. Khodursky AB, Cozzarelli NR: The mechanisms of inhibition of topoisomerase IV by quinolone antibacterials. J Biol Chem 1998, 273:27668-27677.
20. Anderson VE, Gootz TD, Osheroff N: Topoisomerase IV catalysis and the mechanism of quinolone action. J Biol Chem 1998, 273:17879-17885.
21. Wolfson JS, Hooper DC: The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother 1985, 28:581-586.
22. Eliopoulos GM: In vitro activity of new quinolone antimicrobial agents. In Microbiology-1986. Edited by Leive L. Washington DC: American Society for Microbiology, 1986:219-221.
23. Wiedemann B, Grimm H: Susceptibility to antibiotics: species incidence and trends. In Antibiotics in Laboratory Medicine. Edited by Lorian V. Baltimore: Williams & Wilkins; 1996:900-1168.
24. Morisini MI, Loza E, Almaraz F, et al.: In vitro activity of garenoxacin (BMS-284756) against prospectively collected Spanish pneumoniae isolates S. [abstract E-62.] Paper presented at 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego. September 27-30, 2002.
25. Jones RN, Mutnick A, Biedenbach D: Garenoxacin (BMS 284756) activity against 8686 S. pneumoniae (SPN) including tentative susceptibility testing criteria [abstract E-58]. Paper presented at 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego. September 27-30, 2002.
26. Kelly LM, Smith K, Jacobs M, Appelbaum P: Anti-pneumococcal activity of a new quinolone, DK-507k, compared to eleven other agents by MIC methodology [abstract E-572]. Paper presented at 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego. September 27-30, 2002.
27. Ling G, Patel M, Bupte S, et al.: Time kill analysis of the antipneumococcal activity of two new quinolones, WCK 771A and WCK 919, compared to five other quinolones [abstract F-559]. Paper presented at 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego. September 27-30, 2002.
28. Ho PL, Que TL, Tsang DN, et al.: Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrob Agents Chemother 1999, 43:1310-1313.
29. Pestova E, Beyer R, Ciancotto NP, et al.: Contribution of topoisomerase IV and gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones. Antimicrob Agents Chemother 1999,43:2000-2004.
30. Vasquez J, de la Fuente L, Gimenez MJ, et al.: In vitro activity of gemifloxacin and 13 other antimicrobials against 400 Spanish isolates of Neisseria meningitidis collected between 1998-1999 [abstract 132]. Paper presented at 3rd European Congress of Chemotherapy. Madrid. May 7-10, 2000.
31. Blondeau JM, Yaschuk Y: In vitro activities of ciprofloxacin, cefotaxime, ceftriaxone, chloramphenicol and rifampicin against fully susceptible and moderately penicillin-resistant Neisseria meningitidis. Antimicrob Agents Chemother 1995, 39:2577-25769.
32. Richter SS, Gordon KA, Rhomberg PR, et al.: Neisseria meningitidis with decreased susceptibility to penicillin: Report from Sentry antimicrobial surveillance program, North America, 1998-1999. Diag Microb Infect Dis 2001, 41:83-88.
33. Schultz TR, Tapsall JW, White PA, Newton PJ: An invasive isolate of Neisseria meningitidis showing decreased susceptibility to quinolones. Antimicrob Agents Chemother 2000, 44:1166.
34. Garcia-Garrote F, Cercenado E, Martin-Pedroviejo J, et al.: Comparative in vitro activity of the new quinolone gemifloxacin (SB-265805) with other fluoroquinolones against respiratory tract pathogens. J Antimicrob Chemother 2001, 47:681-684.
35. Biedenbach DJ, Jones RN, Pfaller MA, The Sentry Participant Groups (Americas and Europe): Activity of BMS 284756 against 2681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: report from the Sentry Antimicrobial Surveillance program (2000) in Europe, Canada and the United States. Diagn Microb Infect Dis 2001, 39:245-250.
36. Tanaka M, Yamazaki E, Megumi, et al.: In vitro antibacterial activities of DQ-113, a potent quinolone-against clinical isolates. Antimicrob Agents Chemother 2002, 46:904-908.
37. Marco F, Garcia-de-Lomas J, Garcia-Rey C, et al., and the Spanish Surveillance Group for Respiratory Pathogens: Antimicrobial susceptibility of 1730 Haemophilus influenzae respiratory tract isolates in Spain in 1998-1999. Antimicrob Agents Chemother 2001, 45:3226-3228.
38. Montanari MP, Mingoia M, Marchetti F, Varaldo PE: In vitro activity of levofloxacin against gram-positive bacteria. Chemotherapy 1999, 45:411-417.
39. Hoogkamp-Korstanje JAA, Reolofs-Willemse J: Comparative in vitro activity of moxifloxacin against Gram-positive clinical isolates. J Antimicrob Chemother 2000, 45:31-39.
40. Rolston KVI, Frisbee-Hume S, LeBlanc BM, et al.: Antimicrobial activity of a novel des-fluoro(6) quinolone, garenoxacin (BMS-284756), compared to other quinolones, against clinical isolates from cancer patients. Diag Microbiol Infect Dis 2002, 44:187-194.
41. Michelet C, Avril JL, Arvieux C, et al.: Comparative activities of new fluoroquinolones, alone and in combination with amoxicillin, trimethoprim-sulfamethoxate, or rifampicin, against intracellular Listeria monocytogenes. Antimicrob Agents Chemother 1997, 41:60-65.
42. Cherubin CE, Stratton CW: Assessment of the bactericidal activity of sparfloxacin, ofloxaxin, levofloxacin, and other fluoroquinolones compared with selected agents of proven efficacy against Listeria monocytogenes. Diagn Microbiol Infect Dis 1994, 20:21-25.
43. Lutsar I, McCracken G, Friedland IR: Antibiotic pharmacodynamics in cerebrospinal fluid. Clin Infect Dis 1998, 27:1117-1129.
44. Kim MK, Nightingale CH: Pharmacokinetics and pharmacodynamics of the fluoroquinolones. In The Quinolones. Edited by Andriole VT. San Diego: Academic Press; 2000:169-202.
45. Dudley MN: Pharmacodynamics of antibiotics with special reference to the fluoroquinolones. Am J Med 1991, 91(Suppl 6a):45S-50S.
46. Kim YS, Liu Q, Chow LL, et al.: Trovafloxacin in treatment of rabbits with experimental meningitis caused by high-level resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 1997, 41:1186-1189.
47. Rodriguez-Cerrato V, Ghaffar F, Saavedra J, et al.: BMS-284756 in experimental cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 2001, 45:3098-3103.
48. Rodriguez-Cerrato V, McCopig CC, Michelow IC, et al.: Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis. Antimicrob Agents Chemother 2001, 45:3092-3097.
49. Lutsar I, Friedland I, Wubbel L, et al.: Pharmacodynamics of gatifloxacin in cerebrospinal fluid in experimental cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1998, 42:2650-2655.
50. Meng X, Pei Y, Nightingale CH, et al.: Determination of the in vivo post-antibiotic effect of ciprofloxacin and rifampicin. J Antimicrob Chemother 1995, 36:987-996.
51. Firsov AA, Shevchenko AA, Vostrov SN, Zinner SH: Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insights into a widely used concept. Antimicrob Agents Chemother 1998, 42:659-665.
52. Hopkins S, Williams D, Dunne M, et al.: A randomized controlled trial of oral or iv trovafloxacin versus ceftriaxone in the treatment of epidemic meningococcal meningitis. Paper presented at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC. September 15-18, 1996.
53. Saez-Lorenz X, McCoig C, Feris J, et al.: Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxacin and ceftriaxone with or without vancomycin J Pediatr Infect Dis 2002, 21:14-22.
54. Krcmery V, Filka J, Uher J, et al.: Ciprofloxacin in treatment of nosocomial meningitis in neonates and in infants: report of 12 cases and review. Diag Microbiol Infect Dis 1999, 35:75-80.
55. Millar MR, Bransby-Zachary MA, Tompkins DS, et al.: Ciprofloxacin for Pseudomonas aeruginosa meningitis. Lancet 1986, 1:1325.
56. Bhutta Z, Faroqui B, Sturm W: Eradication of a multiple drug resistant Salmonella paratyphi A causing meningitis with ciprofloxacin. J Infect Dis 1992, 25:215-219.
57. Green SD, Ilunga F, Cheesbrough JS, et al.: The treatment of neonatal meningitis due to Gram-negative bacilli with ciprofloxacin: evidence of satisfactory penetration into the cerebrospinal fluid. J Infect Dis 1993, 26:253-256.
58. Lipman J, Allworth A, Walis SC: Cerebrospinal penetration of high doses of intravenous ciprofloxacin in meningitis. Clin Infect Dis 2000, 31:1331-1133.
59. Schmidt H, Dalhoff A, Stuertz K, et al.: Moxifloxacin in the therapy of experimental pneumococcal meningitis. Antimicrob Agents Chemother 1998, 42:1397-1401.
60. Ostergaard C, Sorensen TK, Knudsen JD, et al.: Evaluation of moxifloxacin, a new 8-methoxyquinolone for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits. Antimicrob Agents Chemother 1998, 39:593-597.
61. Perrig M, Acosta F, Cottagnoud M, et al.: Efficacy of gatifloxacin alone and in combination with cefepime against penicillin-resistant Streptococcus pneumoniae in a rabbit meningitis model and in vitro. J Antimicrob Chemother 2001, 47:701-704.
62. Smirnov A, Wellmer A, Gerber J, et al.: Gemifloxacin is effective in experimental pneumococcal meningitis. Antimicrob Agents Chemother 2000, 44:767-770.
63. Cottagnoud P, Acosta F, Cottagnoud M, et al.: Gemifloxacin is efficacious against penicillin-resistant and quinolone-resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother 2002, 46:1607-1609.
64. Gerber CM, Tovar L, Cottagnoud M, et al.: Grepafloxacin against penicillin-resistant pneumococci in the rabbit meningitis model. J Antimicrob Chemother 2000, 46:249-243.
65. Rodriguez-Cerrato V, Ghaffar F, Saavedra J, et al.: BMS-284756 in experimental cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 2001, 45:3098-3103.
66. Takahata M, Yamada H, Morita T, et al.: Evaluation of T-3811ME (BMS-284756), a new des-F(6)-quinolone, for treatment of meningitis caused by penicillin-resistant Streptococcus pneumoniae in rabbits. Antimicrob Agents Chemother 2002, 46:1760-1765.
67. Cottagnoud P, Acosta F, Cottagnoud M, et al.: Efficacies of BMS 284756 against penicillin-sensitive, penicillin-resistant, and quinolone-resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother 2002, 46:184-187.
68. Rodriguez-Cerrato V, McCoig C, Saavedra J, et al.: Garenoxacin (BMS-284756) and moxifloxacin in experimental meningitis caused by vancomycin-tolerant pneumococci. Antimicrob Agents Chemother 2003, 47:211-215.
69. Rodoni D, Haenni F, Gerber CM, et al.: Trovafloxacin in combination with vancomycin against penicillin-resistant pneumococci in the rabbit meningitis model. Antimicrob Agents Chemother 1999, 43:963-965.
70. Cottagnoud P, Acosta F, Cottagnoud M, et al.: Synergy between trovafloxacin and ceftriaxone against penicillin-resistant pneumococci in the rabbit meningitis model and in vitro. Antimicrob Agents Chemother 2000, 44:2179-2181.
71. Flatz L, Cottagnoud M, Acosta F, et al.: Ceftriaxone acts synergistically with levofloxacin against penicillin resistant pneumococci in experimental meningitis and reduces levofloxacin-induced resistance in vitro. Paper presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego. September 27-30, 2002.
72. Michelet C, Leib SL, Bentue-Ferrer D, et al.: Comparative efficacies of antibiotics in a rat model of meningoencephalitis due to Listeria monocytogenes. Antimicrob Agents Chemother 1999, 43:1651-1656.
73. van Deuren M, Brandzaeg P, van der Meer JW: Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbiol Rev 2000, 13:144-166.
74. Philips A, King A, Shannon K: Comparative in-vitro properties of the quinolones. In The Quinolones. Edited by Andriole VT. San Diego: Academic Press; 2002:99-137.
75. Bauernfeind A: Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother 1997, 40:639-651.
76. Tunkel AR: Bacterial meningitis. Philadelphia: Lippincott Williams & Wilkins; 2001.